ArticleRice (New York, N.Y.)2025
Functional Analysis of Mature Activin A Produced by Enterokinase in Plant Cells.
Article in Rice (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Molecular farming for producing biopharmaceuticals in plants is considered an excellent method to replace some of the production methods currently used, and a significant number of recombinant proteins have already shown the potential to facilitate this. In particular, production of activin A, which has a variety of important biological functions in humans, is limited. The purpose of this study was to develop a safe, stable, and efficient plant-based in vitro production system for activin A, assess its biological activity in cancer cells, and demonstrate its potential for use in cancer research. We evaluated the expression and production of activin A in plant cells through a mass culture and secretion system. The formation of mature activin A homodimers, produced by enterokinase, was also assessed. Southern blot and inverse PCR were performed to investigate the gene insertion sites in the plants, and the stability of activin A was evaluated over six months under various pH conditions. The activity of plant-derived activin A was analyzed in HEK293T, Huh7, MCF7, and MDA-MB-231 cancer cell lines using luciferase reporter, migration, phosphorylation, and gelatin zymography assays. We developed cell line #71, which showed the highest levels of mature activin A expression (8.44 μg/g calli fresh weight) and had multicopy gene insertions. Pro-activin A was converted to mature activin A using enterokinase. We demonstrated that the optimal stability of plant-derived activin A was maintained for six months at pH 7 below 4 °C. Plant-derived activin A significantly enhanced activin A signaling activity in HEK293T, Huh7, and MCF7 cancer cells. Additionally, we confirmed that plant-derived activin A inhibited the growth of Huh7 cancer cells by activating the Smad pathway without affecting the MAPK pathway. Contrastingly, in MDA-MB-231 breast cancer cells, plant-derived activin A promoted cell migration. Our results confirm that plant-derived activin A, produced using a mass production system, exhibits full biological activity and affects cancer cell behavior in a manner similar to activin A derived from traditional mammalian systems. Furthermore, this study highlights the importance of considering cellular context when determining the functional outcomes of activin A treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.